Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Gastrointestinal, Pancreatic, or Colorectal Cancer

Model scores of the 29,894 trials active now.

Model score 26% for any early termination, 6% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 16% of the time (927 trials).

Finished trial that started in 2015 or later: the model never saw it during training.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2025-01-09. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: subject haschemotherapyor equalsubjectsthe subject
  Phrases that lowered it: malelaboratoryaminotransferasescreeningprostate
• Accepts healthy volunteers: No (raises risk) · Who can join
• Sponsor's past termination rate: 11.0% (raises risk) · Sponsor's track record
• Maximum age: 100 (lowers risk) · Who can join
• Phase: 3 (lowers risk) · Design
• Has a data monitoring committee: Yes (raises risk) · Design
• Disease area, cancer: Yes (raises risk) · Disease area
• Trials the sponsor started in the prior 2 years: 64 (lowers risk) · Sponsor's track record
• Design: parallel (raises risk) · Design
• Sponsor type: industry (lowers risk) · Sponsor's track record
• Minimum age: 18 (raises risk) · Who can join
• Primary purpose: treatment (raises risk) · Design
• Blinding: double (raises risk) · Design
• Drug's FAERS reports with a death: 19.7% (lowers risk) · Drug's FDA history
• Sponsor's past trials: 544 (lowers risk) · Sponsor's track record
• Responsible party: sponsor (lowers risk) · Design
• Drug's FAERS reports before start: 10470 (raises risk) · Drug's FDA history
• Drug's FAERS reports marked serious: 81.2% (lowers risk) · Drug's FDA history
• Drug's FAERS reports in the prior 12 months: 582 (raises risk) · Drug's FDA history

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Using Romiplostim to Treat Low Platelet Counts During Chemotherapy in People With Lymphoma NCT04673266 · started 2020 · scored riskier than 60% of active trials completed
• Patients With Relapsed Ovarian Cancer (2nd and 3rd Line) Treated With Chemotherapy According to AGO Guidelines NCT03622931 · started 2014 · scored riskier than 92% of active trials terminated
• Safety and Efficacy Study for Solid Tumor Patients Treated With Eltrombopag NCT01147809 · started 2010 · scored riskier than 75% of active trials completed
• A Study of PN20 for the Prevention of Chemotherapy-induced Thrombocytopenia in Lymphoma or Solid Tumor Patients NCT06521931 · started 2023 · scored riskier than 20% of active trials completed
• Ulixertinib (BVD-523) and Hydroxychloroquine in Patients W Advanced MAPK-Mutated Gastrointestinal Adenocarcinomas NCT04145297 · started 2020 · scored riskier than 93% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.